Alzamend Neuro Inc

ALZN | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.94

+$0.05 (+2.65%)

At close: Sep 21, 2026, 4:00 PM ET

$1.93

-$0.01 (-0.52%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+2.65%

(1D)

Rating

Updated: Aug 25, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $7.38M

1D Range

1.87 1.94

52W Range

0.84 2.68

Valuation (TTM)

PE -0.84

PB 1.27

EV/EBITDA 0.02

Valuation (NTM)

Forward PE N/A

Forward PEG 0.05

Price Target $26

Cash Flow

FCF Yield -92.7%

SBC Adj. FCF Yield -94.3%

SBC Impact -1.7%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 131.0% | 56.8%

FCF 3Y | 5Y -5.2% | 5.3%

Returns

ROA -106.5%

ROE -277.9%

ROIC -156.7%

Financial Health

Net Cash

$7.59M

Current Ratio 3.01

Interest Coverage 818.59

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, ...

Sector Healthcare

Industry Biotechnology

Employees 6

IPO Date Jun 14, 2021

Website www.alzamend.com

Fiscal Year May - April

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$26

Upside

+1240.21%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞